Shamburg News · 8-K filed Nov 16, 2026, 4:10 PM EST
Enanta Pharmaceuticals Reports Fiscal Fourth Quarter and Year 2026 Results
ENTA · ENANTA PHARMACEUTICALS INC
- Earnings
- Leadership change
- Materiality: high
Enanta Pharmaceuticals reported total revenue of $12.9 million for the three months ended September 30, 2026, compared with $15.1 million a year earlier, and a net loss of $23.7 million, or $0.81 per diluted share. For the twelve months ended September 30, 2026, revenue was $63.0 million and the net loss was $68.2 million, or $2.35 per diluted share. The company also announced that President and CEO Jay R. Luly, Ph.D., will retire by February 2027 and that Tara L. Kieffer, Ph.D., was named Chief Operating Officer; cash and marketable securities totaled $194.5 million at September 30, 2026.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-463508.
Written from the filing by Shamburg Markets. Figures are as reported by the company.